Azizian, Azadeh

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Azizian, A."],["dc.contributor.author","Bernhardt, M."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Koenig, A."],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T10:20:53Z"],["dc.date.available","2018-11-07T10:20:53Z"],["dc.date.issued","2016"],["dc.format.extent","75"],["dc.identifier.isi","000371353700239"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41971"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Heterogeneity of KRAS Mutation Status in Rectal Cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Langenbeck's Archives of Surgery"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Ghadimi, Michael"],["dc.date.accessioned","2022-09-01T09:51:31Z"],["dc.date.available","2022-09-01T09:51:31Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract\n \n Purpose\n VIPoma belongs to the group of neuroendocrine neoplasms. These tumours are located mostly in the pancreas and produce high levels of vasoactive intestinal peptide (VIP). In most cases, a metastatic state has already been reached at the initial diagnosis, with high levels of VIP leading to a wide spectrum of presenting symptoms. These symptoms include intense diarrhoea and subsequent hypopotassaemia but also cardiac complications, with life-threatening consequences. Treatment options include symptomatic therapy, systemic chemotherapy and targeted therapy, as well as radiation and surgery. Due to the low incidence of VIPoma, there are no prospective studies or evidence-based therapeutic standards to date.\n \n \n Methods\n To evaluate the possible impact of different therapy strategies, we performed literature research using PubMed.\n \n \n Results\n All possible treatment modalities for VIPoma have at least one of two therapy goals: antisecretory effects (symptom control) and antitumoural effects (tumour burden reduction). Symptomatic therapy is the most important in the emergency setting to rehydrate, balance electrolytes and stabilise the patient. Symptomatic therapy is also of great importance perioperatively. Somatostatin analogues play a major role in symptom control, although their efficiency is often limited. Chemotherapy may be effective in reaching stable disease for a certain time period, although its impact on symptom control is limited and often delayed. Among targeted therapy options, the usage of sunitinib appears to be the most effective in terms of symptom control and showing antitumoural effects at the same time. Experience with radiation is still limited; however, local ablative procedures seem to be promising options. Peptide receptor radiotherapy (PRRT) with radiolabelled somatostatin analogues (SSAs, 177Lu-DOTATATE) offers a targeted approach, especially in patients with high somatostatin receptor density. Surgery is the first-line therapy for nonmetastatic VIPoma. Additionally, if the resection of all visible tumour lesions is possible, the surgical approach seems preferable to other strategies in highly symptomatic patients. The role of surgery in very advanced stages where only tumour debulking is possible remains debatable. However, a high rate of immediate symptom control can be achieved by tumour debulking followed by somatostatin therapy, although the impact on survival remains unclear.\n \n \n Conclusion\n Surgery is the only curative option for nonmetastatic VIPoma. Additionally, surgery should be a first-line therapy option for highly symptomatic patients, especially if the resection of all tumour lesions (primary tumour and metastasis) is achievable. In frail patients, other modalities can be used."],["dc.identifier.doi","10.1007/s00423-022-02620-7"],["dc.identifier.pii","2620"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113988"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","1435-2451"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Treatment options of metastatic and nonmetastatic VIPoma: a review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Azizian, A."],["dc.contributor.author","Salendo, Junius"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T09:44:05Z"],["dc.date.available","2018-11-07T09:44:05Z"],["dc.date.issued","2014"],["dc.format.extent","7"],["dc.identifier.isi","000332306700021"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34318"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Circulating microRNAs to monitor preoperative CRT in rectal cancer patients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1134"],["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Kensah, George"],["dc.contributor.author","Lara, Angelica Roa"],["dc.contributor.author","Dahlmann, Julia"],["dc.contributor.author","Zweigerdt, Robert"],["dc.contributor.author","Schwanke, Kristin"],["dc.contributor.author","Hegermann, Jan"],["dc.contributor.author","Skvorc, David"],["dc.contributor.author","Gawol, Anke"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Wagner, Stefan"],["dc.contributor.author","Maier, Lars. S."],["dc.contributor.author","Krause, Andreas"],["dc.contributor.author","Draeger, Gerald"],["dc.contributor.author","Ochs, Matthias"],["dc.contributor.author","Haverich, Axel"],["dc.contributor.author","Gruh, Ina"],["dc.contributor.author","Martin, Ulrich"],["dc.date.accessioned","2018-11-07T09:26:20Z"],["dc.date.available","2018-11-07T09:26:20Z"],["dc.date.issued","2013"],["dc.description.abstract","We explored the use of highly purified murine and human pluripotent stem cell (PSC)-derived cardiomyocytes (CMs) to generate functional bioartificial cardiac tissue (BCT) and investigated the role of fibroblasts, ascorbic acid (AA), and mechanical stimuli on tissue formation, maturation, and functionality. Murine and human embryonic/induced PSC-derived CMs were genetically enriched to generate three-dimensional CM aggregates, termed cardiac bodies (CBs). Addressing the critical limitation of major CM loss after single-cell dissociation, non-dissociated CBs were used for BCT generation, which resulted in a structurally and functionally homogenous syncytium. Continuous in situ characterization of BCTs, for 21 days, revealed that three critical factors cooperatively improve BCT formation and function: both (i) addition of fibroblasts and (ii) ascorbic acid supplementation support extracellular matrix remodelling and CB fusion, and (iii) increasing static stretch supports sarcomere alignment and CM coupling. All factors together considerably enhanced the contractility of murine and human BCTs, leading to a so far unparalleled active tension of 4.4 mN/mm(2) in human BCTs using optimized conditions. Finally, advanced protocols were implemented for the generation of human PSC-derived cardiac tissue using a defined animal-free matrix composition. BCT with contractile forces comparable with native myocardium can be generated from enriched, PSC-derived CMs, based on a novel concept of tissue formation from non-dissociated cardiac cell aggregates. In combination with the successful generation of tissue using a defined animal-free matrix, this represents a major step towards clinical applicability of stem cell-based heart tissue for myocardial repair."],["dc.identifier.doi","10.1093/eurheartj/ehs349"],["dc.identifier.isi","000318077500012"],["dc.identifier.pmid","23103664"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30278"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","0195-668X"],["dc.title","Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardial tissue in vitro"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","1140"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","International Journal of Molecular Sciences"],["dc.bibliographiccitation.volume","18"],["dc.contributor.affiliation","Jo, Peter; \t\t \r\n\t\t Department of General-, Visceral-, and Pediatric Surgery, University Medical Center Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany, jo.peter@chirurgie-goettingen.de"],["dc.contributor.affiliation","Azizian, Azadeh; \t\t \r\n\t\t Department of General-, Visceral-, and Pediatric Surgery, University Medical Center Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany, azadeh.azizian@med.uni-goettingen.de"],["dc.contributor.affiliation","Salendo, Junius; \t\t \r\n\t\t Department of General-, Visceral-, and Pediatric Surgery, University Medical Center Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany, juniussalendo@gmail.com"],["dc.contributor.affiliation","Kramer, Frank; \t\t \r\n\t\t Department of Medical Statistics, University Medical Center Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany, frank.kramer@med.uni-goettingen.de"],["dc.contributor.affiliation","Bernhardt, Markus; \t\t \r\n\t\t Department of General-, Visceral-, and Pediatric Surgery, University Medical Center Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany, markus.bernhardt@med.uni-goettingen.de"],["dc.contributor.affiliation","Wolff, Hendrik; \t\t \r\n\t\t Department of Radiology, Nuclear Medicine and Radiotherapy, Radiology Munich, Burgstr. 7, 80333 Munich, Germany, drhawolff@googlemail.com"],["dc.contributor.affiliation","Gruber, Jens; \t\t \r\n\t\t German Primate Center, Medical RNA Biology, Kellnerweg 4, 37075 Goettingen, Germany, jgruber@dpz.eu"],["dc.contributor.affiliation","Grade, Marian; \t\t \r\n\t\t Department of General-, Visceral-, and Pediatric Surgery, University Medical Center Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany, marian.grade@med.uni-goettingen.de"],["dc.contributor.affiliation","Beißbarth, Tim; \t\t \r\n\t\t Department of Medical Statistics, University Medical Center Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany, tim.beissbarth@med.uni-goettingen.de"],["dc.contributor.affiliation","Ghadimi, B.; \t\t \r\n\t\t Department of General-, Visceral-, and Pediatric Surgery, University Medical Center Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany, mghadim@uni-goettingen.de"],["dc.contributor.affiliation","Gaedcke, Jochen; \t\t \r\n\t\t Department of General-, Visceral-, and Pediatric Surgery, University Medical Center Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany, jochen.gaedcke@med.uni-goettingen.de"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Salendo, Junius"],["dc.contributor.author","Kramer, Frank"],["dc.contributor.author","Bernhardt, Markus"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Gruber, Jens"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T10:22:50Z"],["dc.date.available","2018-11-07T10:22:50Z"],["dc.date.issued","2017"],["dc.date.updated","2022-09-06T05:14:56Z"],["dc.description.abstract","Since the response to chemoradiotherapy in patients with locally advanced rectal cancer is heterogeneous, valid biomarkers are needed to monitor tumor response. Circulating microRNAs are promising candidates, however analyses of circulating microRNAs in rectal cancer are still rare. 111 patients with rectal cancer and 46 age-matched normal controls were enrolled. The expression levels of 30 microRNAs were analyzed in 17 pre-treatment patients' plasma samples. Differentially regulated microRNAs were validated in 94 independent patients. For 52 of the 94 patients a paired comparison between pre-treatment and post-treatment samples was performed. miR-17, miR-18b, miR-20a, miR-31, and miR-193a_3p, were significantly downregulated in pre-treatment plasma samples of patients with rectal cancer (p < 0.05). miR-29c, miR-30c, and miR-195 showed a trend of differential regulation. After validation, miR-31 and miR-30c were significantly deregulated by a decrease of expression. In 52 patients expression analyses of the 8 microRNAs in matched pre-treatment and post-treatment samples showed a significant decrease for all microRNAs (p < 0.05) after treatment. Expression levels of miR-31 and miR-30c could serve as valid biomarkers if validated in a prospective study. Plasma microRNA expression levels do not necessarily represent miRNA expression levels in tumor tissue. Also, expression levels of microRNAs change during multimodal therapy."],["dc.description.sponsorship","DFG (German Research Foundation)"],["dc.identifier.doi","10.3390/ijms18061140"],["dc.identifier.isi","000404581500040"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14793"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42349"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Mdpi Ag"],["dc.relation.eissn","1422-0067"],["dc.relation.issn","1422-0067"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Changes of Microrna Levels in Plasma of Patients with Rectal Cancer during Chemoradiotherapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e2223225"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","JAMA Network Open"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Rühlmann, Felix"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Mackert, Alma Franziska"],["dc.contributor.author","Engelhardt, Deborah"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Bernhardt, Markus"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Perl, Thorsten"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2022-09-01T09:49:15Z"],["dc.date.available","2022-09-01T09:49:15Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1001/jamanetworkopen.2022.23225"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113381"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","2574-3805"],["dc.title","Incidence, Associated Risk Factors, and Outcomes of Postoperative Arrhythmia After Upper Gastrointestinal Surgery"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","416"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","World Journal of Gastrointestinal Oncology"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Gruber, Jens"],["dc.contributor.author","Ghadimi, B Michael"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2020-12-10T18:47:48Z"],["dc.date.available","2020-12-10T18:47:48Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.4251/wjgo.v8.i5.416"],["dc.identifier.issn","1948-5204"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78894"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","MicroRNA in rectal cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","175628482110511"],["dc.bibliographiccitation.journal","Therapeutic Advances in Gastroenterology"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Hartmann, Amelie"],["dc.contributor.author","Schuppert, Frank"],["dc.contributor.author","Seif Amir Hosseini, Ali"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Ghadimi, Michael"],["dc.date.accessioned","2022-01-11T14:08:01Z"],["dc.date.available","2022-01-11T14:08:01Z"],["dc.date.issued","2021"],["dc.description.abstract","VIPoma, a neuroendocrine tumour mostly occurring in the human pancreas and producing high levels of vasoactive intestinal peptide, is a rare disease that presents with a wide spectrum of symptoms, including intense diarrhoea, hypokalaemia, and cardiac complications, with life-threatening consequences. In most cases, metastatic lesions are present at VIPoma diagnosis. Treatment options include symptomatic therapy, chemotherapy, radiation and surgery. Due to its low incidence, there are no evidence-based therapy recommendations to date. Here, we present a case of a 39-year-old woman with severe symptoms due to VIPoma of the pancreas with diffuse hepatic metastasis, who underwent simultaneous resection of the primary tumour, extensive liver resection and radiofrequency ablation. The patient was released in good health and was recurrence-free during 12 months surveillance. According to the existing literature and our own experience, surgical procedures appear to be the most promising therapy option for cases with diffuse hepatic metastasis, offering patients relief from their symptoms and (chemo)therapy-free time."],["dc.identifier.doi","10.1177/17562848211051132"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/97916"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-507"],["dc.relation.issn","1756-2848"],["dc.rights","CC BY-NC 4.0"],["dc.title","Surgical treatment of metastatic VIPoma: a case report"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Rühlmann, Felix"],["dc.contributor.author","Krause, Tanja"],["dc.contributor.author","Bernhardt, Markus"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Kleiß, Mathias"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2021-04-14T08:27:35Z"],["dc.date.available","2021-04-14T08:27:35Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1038/s41598-020-57930-x"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82341"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","2045-2322"],["dc.title","CA19-9 for detecting recurrence of pancreatic cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","568"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Molecular Sciences"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Epping, Ingo"],["dc.contributor.author","Kramer, Frank"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Bernhardt, Markus"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Salinas, Gabriela"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Beissbarath, Tim"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T10:16:01Z"],["dc.date.available","2018-11-07T10:16:01Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Patients with locally advanced rectal cancer are treated with preoperative chemoradiotherapy followed by surgical resection. Despite similar clinical parameters (uT2-3, uN+) and standard therapy, patients' prognoses differ widely. A possible prediction of prognosis through microRNAs as biomarkers out of treatment-naive biopsies would allow individualized therapy options. Methods: Microarray analysis of 45 microdissected preoperative biopsies from patients with rectal cancer was performed to identify potential microRNAs to predict overall survival, disease-free survival, cancer-specific survival, distant-metastasis-free survival, tumor regression grade, or nodal stage. Quantitative real-time polymerase chain reaction (qPCR) was performed on an independent set of 147 rectal cancer patients to validate relevant miRNAs. Results: In the microarray screen, 14 microRNAs were significantly correlated to overall survival. Five microRNAs were included from previous work. Finally, 19 miRNAs were evaluated by qPCR. miR-515-5p, miR-573, miR-579 and miR-802 demonstrated significant correlation with overall survival and cancer-specific survival (p<0.05). miR-573 was also significantly correlated with the tumor regression grade after preoperative chemoradiotherapy. miR-133b showed a significant correlation with distant-metastasis-free survival. miR-146b expression levels showed a significant correlation with nodal stage. Conclusion: Specific microRNAs can be used as biomarkers to predict prognosis of patients with rectal cancer and possibly stratify patients' therapy if validated in a prospective study."],["dc.identifier.doi","10.3390/ijms17040568"],["dc.identifier.isi","000374585300147"],["dc.identifier.pmid","27092493"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13222"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40949"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Mdpi Ag"],["dc.relation.issn","1422-0067"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Prognostic Value of MicroRNAs in Preoperative Treated Rectal Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]